TABLE 2.
Development of heterologous neutralizing antibody responses
| Virus | % Inhibition (SD)a
|
|||||
|---|---|---|---|---|---|---|
| C640
|
A141
|
A03065 (197 dpi) | AT54 (111 dpi) | |||
| 304 dpi | 643 dpi | 214 dpi | 670 dpi | |||
| SF162 | 98 (0.5) | 99 (0.5) | 99 (0.5) | 97 (3) | 96.5 (3) | 32.5 (4) |
| ADA | 61.5 (7) | 81 (6) | 23 (10.5) | 28 (3) | 25 (10) | 11 (10) |
| JRFL | 99 (0.5) | 95 (4) | 37 (18) | 42 (4) | 23 (12) | 2 (2) |
| YU2 | 53 (7) | 87 (2) | 34 (26) | 34 (2) | 5 (5) | 22 (2) |
| 89.6 | 71 (4) | 71 (15) | 71 (12) | 90 (2) | 84 (5) | 3 (3) |
| HxB2 | 93 (3) | 98 (0) | 94 (3) | NT | 97 (2) | NT |
| 3988 | 12 (32) | 65 (9) | 5 (40) | 45 (2.5) | 3 (2) | 22 (5) |
| 6101 | 10 (6) | 53 (13) | 5 (8) | 57.0 (6.5) | 5 (8) | NT |
| 6535 | 63 (14) | 95 (3) | 70 (5) | 70 (8) | 66.5 (4) | 5 (8) |
| PVO.4 | 42.5 (11) | 65 (6) | 14 (21) | 37 (5) | 6 (8) | 38 (10) |
| QH0692.42 | 38.5 (12) | 59 (10) | 29 (17.5) | 75 (30) | 9 (14) | 12 (0.5) |
| REJO.67 | 21 (10) | 53 (22) | 24 (31) | 68 (3) | 8 (12) | 13.5 (1.5) |
| SC422661.8 | 4 (35) | 76 (2) | 1 (55) | 47.0 (6.0) | 3 (2) | 30 (9) |
| SS1196.1 | 86 (6.5) | 77 (17) | 62 (10) | 91 (0.5) | 97 (2) | 4 (8) |
| TRO11 | 20.5 (33) | 66 (6) | 3 (47) | 53 (6.5) | 6 (2) | 8.5 (5) |
| TRJO | 23.5 (26) | 56 (9) | 58 (28) | 28.0 (18.5) | 5 (5) | 10 (6) |
| 5768 | 4.0 (27) | 44 (15) | 8 (49) | 23 (5) | 7 (9) | 6 (7) |
| 7165 | 6 (9) | 40 (16) | 20 (33) | 63 (31) | 5 (5) | 6 (10) |
| AR29 | 15 (13) | 28 (5) | 27 (26) | 37 (7) | 6 (1) | 16 (7) |
| BG1168 | 10 (18) | 40 (8) | 8 (28) | 38 (1) | 4 (7) | 38 (4) |
| CAAN.A2 | 20 (16) | 38 (0.5) | 4 (16) | 35 (4) | 7 (5) | 3 (10) |
| QH0515 | 40 (25) | 40 (9) | 14 (45) | 37 (4) | 8 (10) | NT |
| RHPA | 25 (20) | 25 (17) | 2 (27) | 32 (7) | 6 (12) | 8 (8) |
| WITO | 19 (13) | 41 (7) | 30 (28) | 16 (12) | 15 (12) | 5 (5) |
| MLV | 10 (23) | 9 (21) | 15 (20) | 21 (16) | 3 (28) | 3.5 (17) |
a
The values are the percent inhibition of infection recorded at a single (1:20) serum dilution. The mean percent inhibition from two independent experiments is shown. Murine leukemia virus (MLV) was used as a control for nonspecific neutralization. Neutralization was considered significant (values in boldface) when the value was at least twice that obtained with the unrelated MLV virus and greater than 50%. *, Day of euthanasia; NT, not tested.